Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketdailypress.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketDailyPress.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent ISRG Stock Price: $250.55
Summary: Intuitive Surgical Inc designs, manufactures and markets the da Vinci surgical system and related instruments and accessories, which is an advanced robot-assisted surgical system. The surgical system comprises a surgeon's console, patient-side cart, 3-D vision system, da Vinci Skills Simulator and Firefly Fluorescence Imaging. Intuitive Surgical's robot-based da Vinci surgical system enables minimally-invasive surgery that reduces the trauma associated with open surgery. The company also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures.'Additionally, the company sells various accessories comprising sterile drapes and vision products and other items that facilitate use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. The company operates through three segments: Instruments and Accessories, Systems and Services.
Jayson Bedford analyst at Raymond James reiterates coverage on Intuitive Surgical (ISRG) stock in the energy sector with a Buy rating and has set ISRG's stock price target at $ 270.
TipRanks.com reports that Intuitive Surgical currently has 15 analysts offering 12-month price targets on ISRG and the consensus is a Moderate Buy rating with an average stock price target of $277.40. The most recent ISRG stock price we have is $250.55 and we are not making any ISRG forecasts at this time.
In addition, TradingView issued a Neutral rating for ISRG over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ISRG. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ISRG, please click here >>
Abbott Labs, ABT
Recent ABT Stock Price: $111.07
Summary: Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
Jayson Bedford analyst at Raymond James reiterates coverage on Abbott Labs (ABT) stock in the energy sector with a Buy rating and has set ABT's stock price target at $ 123.
TipRanks.com reports that Abbott Labs currently has 11 analysts offering 12-month price targets on ABT and the consensus is a Moderate Buy rating with an average stock price target of $123.55. The most recent ABT stock price we have is $111.07 and we are not making any ABT forecasts at this time.
In addition, TradingView issued a Buy rating for ABT over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ABT. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ABT, please click here >>
Danaher, DHR
Recent DHR Stock Price: $265.86
Summary: Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of critical areas including genes, proteins, metabolites and cells to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. Diagnostics segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions. Environmental & Applied Solutions segment offers products and services that help keep food and water supplies safe globally.
Brandon Couillard analyst at Jefferies reiterates coverage on Danaher (DHR) stock in the energy sector with a Buy rating and has set DHR's stock price target at $ 310.
TipRanks.com reports that Danaher currently has 11 analysts offering 12-month price targets on DHR and the consensus is a Moderate Buy rating with an average stock price target of $300.27. The most recent DHR stock price we have is $265.86 and we are not making any DHR forecasts at this time.
In addition, TradingView issued a Sell rating for DHR over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on DHR. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DHR, please click here >>
Intercept Pharma, ICPT
Recent ICPT Stock Price: $18.37
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
Yasmeen Rahimi analyst at Piper Sandler reiterates coverage on Intercept Pharma (ICPT) stock in the energy sector with a Buy rating and has set ICPT's stock price target at $ 49.
TipRanks.com reports that Intercept Pharma currently has 10 analysts offering 12-month price targets on ICPT and the consensus is a Moderate Buy rating with an average stock price target of $26.13. The most recent ICPT stock price we have is $18.37 and we are not making any ICPT forecasts at this time.
In addition, TradingView issued a Buy rating for ICPT over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ICPT, please click here >>
Roche Holding AG, RHHVF
Recent RHHVF Stock Price: $312.5
Summary: Roche Holding AG Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. It has more than 60 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Diagnostics division includes five business areas: Applied Science, Molecular Diagnostics, Professional Diagnostics, Tissue Diagnosis and Diabetes Care.
Emily Field analyst at Barclays reiterates coverage on Roche Holding AG (RHHVF) stock in the energy sector with a Buy rating and has set RHHVF's stock price target at $ 381.59.
TipRanks.com reports that Roche Holding AG currently has 12 analysts offering 12-month price targets on RHHVF and the consensus is a Hold rating with an average stock price target of $371.78. The most recent RHHVF stock price we have is $312.5 and we are not making any RHHVF forecasts at this time.
In addition, TradingView issued a Sell rating for RHHVF over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on RHHVF. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RHHVF, please click here >>
The editors at marketdailypress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketDailyPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to MarketDailyPress.com.
==============================================================================
